Reviva Pharmaceuticals Holdings, Inc., a clinical development pharmaceutical company, has been making strides in addressing unmet medical needs across various therapeutic areas, including central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. As a global entity, Reviva Pharmaceuticals serves a diverse customer base worldwide, with its operations and developments accessible through its official website, www.revivapharma.com .

Founded with a mission to innovate and develop internally discovered therapies, Reviva Pharmaceuticals has positioned itself as a key player in the health care sector. The company’s focus on CNS, cardiovascular, metabolic, and inflammatory diseases underscores its commitment to tackling some of the most challenging health issues faced by patients globally.

Reviva Pharmaceuticals went public on August 21, 2018, through an initial public offering (IPO) on the Nasdaq stock exchange. This pivotal moment marked the company’s transition from a private entity to a publicly traded company, allowing it to access broader capital markets and fuel its research and development initiatives.

As of October 23, 2025, Reviva Pharmaceuticals’ stock closed at $0.68, reflecting a significant fluctuation over the past year. The company’s 52-week high was recorded at $4.28 on December 8, 2024, while its 52-week low stood at $0.25 on September 18, 2025. These figures highlight the volatility in the company’s stock performance, influenced by various market dynamics and investor sentiments.

With a market capitalization of $65,060,000 USD, Reviva Pharmaceuticals continues to navigate the complexities of the pharmaceutical industry. The company’s price-to-earnings (P/E) ratio of -1.05 indicates that it is currently not generating positive earnings, a common scenario for companies heavily invested in research and development.

Despite these financial metrics, Reviva Pharmaceuticals remains steadfast in its pursuit of groundbreaking therapies. The company’s dedication to addressing unmet medical needs through innovative solutions is a testament to its long-term vision and commitment to improving patient outcomes.

As Reviva Pharmaceuticals progresses in its clinical development efforts, it remains a noteworthy entity in the health care sector. Its focus on critical therapeutic areas and its global reach position it as a potential catalyst for advancements in medical treatments, offering hope to patients and healthcare providers alike.

In conclusion, Reviva Pharmaceuticals Holdings, Inc. exemplifies the challenges and opportunities inherent in the pharmaceutical industry. With its strategic focus on unmet medical needs and its global presence, the company continues to strive towards its mission of developing transformative therapies that can make a significant impact on public health.